title: Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas.
abstract: OBJECTIVE
  To report the effect of cabergoline on ovarian hyperstimulation syndrome associated with gonadotropin-secreting pituitary adenomas.
  
  
  METHODS
  Case report.
  
  
  METHODS
  Outpatient practice.
  
  
  METHODS
  Two women with menstrual irregularity, enlarged ovaries, high E(2), and normal gonadotropin levels.
  
  
  METHODS
  Cabergoline treatment and transsphenoidal surgery.
  
  
  METHODS
  Estradiol levels, transvaginal ultrasonography, and pituitary magnetic resonance imaging. Transsphenoidal surgery showed pituitary adenoma staining for LH in both patients.
  
  
  RESULTS
  Cabergoline was effective in reducing E(2) levels and decreasing ovarian size but ineffective in shrinking the pituitary adenomas.
  
  
  CONCLUSIONS
  This is the first description of the effectiveness of cabergoline as the primary treatment of spontaneous ovarian hyperstimulation syndrome in patients with gonadotropin-producing pituitary adenomas.
authors.affiliation: Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular LIM/42, Disciplina de Endocrinologia e Metabologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. mirta@uol.com.br
authors.forename: Mirta
authors.initials: M
authors.lastname: Knoepfelmacher
authors.forename: Debora L S
authors.initials: DL
authors.lastname: Danilovic
authors.forename: Rubia H R
authors.initials: RH
authors.lastname: Rosa Nasser
authors.forename: Berenice B
authors.initials: BB
authors.lastname: Mendonça
mesh_terms: D000236:Adenoma; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077465:Cabergoline; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006062:Gonadotropins / Q000378:metabolism*; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D004873:Ergolines; D006062:Gonadotropins; D000077465:Cabergoline